Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer.
Caitlin E TaylorJane MeiselAimee J ForemanChristy RussellDipankar BandyopadhyayXiaoyan DengLisa FloydAmelia ZelnakHarry BearRuth O'ReganPublished in: Breast cancer research and treatment (2023)
These data suggest that Recurrence Score® (RS) results may serve as a useful tool in treatment decision-making in the neoadjuvant setting.